In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 ...

Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...

Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...

Each April, thousands of leaders across the pharmaceutical and life sciences industry converge in Las Vegas for the Asembia ...

AbbVie has announced a $1.4 billion investment to build a new pharmaceutical manufacturing campus in North Carolina, ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...

INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...

Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...

IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...